|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
22
|
|
pubmed:dateCreated |
2008-11-17
|
|
pubmed:abstractText |
Prostate cancer remains the second most frequent cause of tumor-related deaths in the Western world. Additional markers for the identification of prostate cancer development and progression are needed. Osteopontin (OPN), which activates matrix metalloproteinases (MMP), is considered a prognostic biomarker in several cancers. "In silico" and experimental approaches were used to determine whether OPN-mediated MMP activation may be a signal of prostate cancer progression.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Nov
|
|
pubmed:issn |
1078-0432
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:day |
15
|
|
pubmed:volume |
14
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
7470-80
|
|
pubmed:meshHeading |
pubmed-meshheading:19010864-Aged,
pubmed-meshheading:19010864-Disease Progression,
pubmed-meshheading:19010864-Enzyme Activation,
pubmed-meshheading:19010864-Enzyme-Linked Immunosorbent Assay,
pubmed-meshheading:19010864-Gene Expression,
pubmed-meshheading:19010864-Gene Expression Profiling,
pubmed-meshheading:19010864-Humans,
pubmed-meshheading:19010864-Immunohistochemistry,
pubmed-meshheading:19010864-Male,
pubmed-meshheading:19010864-Matrix Metalloproteinase 9,
pubmed-meshheading:19010864-Middle Aged,
pubmed-meshheading:19010864-Osteopontin,
pubmed-meshheading:19010864-Prostatic Neoplasms,
pubmed-meshheading:19010864-Signal Transduction
|
|
pubmed:year |
2008
|
|
pubmed:articleTitle |
Activation of the osteopontin/matrix metalloproteinase-9 pathway correlates with prostate cancer progression.
|
|
pubmed:affiliation |
Unit of Molecular Therapies, Department of Experimental Oncology, Fondazione IRCCS, Istituto Nazionale dei Tumori, Milan, Italy.
|
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|
